PTC Therapeutics Withdraws Translarna NDA After FDA Feedback

The latest announcement is out from PTC Therapeutics ( (PTCT) ).

On February 12, 2026, PTC Therapeutics withdrew its New Drug Application resubmission for Translarna (ataluren), a protein restoration therapy for nonsense mutation Duchenne muscular dystrophy, after the U.S. Food and Drug Administration indicated the data were unlikely to meet its threshold for substantial evidence of effectiveness. The decision halts PTC’s two-decade effort to secure U.S. approval for Translarna in this rare and fatal neuromuscular disease, underscoring regulatory hurdles in rare disease drug development and potentially affecting patient access and the company’s positioning in the DMD treatment landscape.

The most recent analyst rating on (PTCT) stock is a Hold with a $75.00 price target. To see the full list of analyst forecasts on PTC Therapeutics stock, see the PTCT Stock Forecast page.

Spark’s Take on PTCT Stock

According to Spark, TipRanks’ AI Analyst, PTCT is a Outperform.

The score is led by strong recent operating performance and cash generation, plus positive commercial traction and guidance around Sephience. It’s held back primarily by balance-sheet leverage/negative equity and some execution risks (payer timelines, Emflaza uncertainty), while technicals and a low P/E provide additional support.

To see Spark’s full report on PTCT stock, click here.

More about PTC Therapeutics

PTC Therapeutics, Inc. is a global biopharmaceutical company focused on discovering, developing and commercializing clinically differentiated medicines for children and adults with rare disorders. The company advances a diversified pipeline of transformative therapies and leverages its scientific expertise and global commercial infrastructure to provide treatments for patients with high unmet medical needs.

Average Trading Volume: 1,584,721

Technical Sentiment Signal: Buy

Current Market Cap: $5.79B

See more insights into PTCT stock on TipRanks’ Stock Analysis page.